; Whereas the importance of medication abortion is recognized globally, and the World Health Organization has included mifepristone on its list of essential medicines since 2005; Whereas the safety record of mifepristone is demonstrated by its availability in more than 90 countries, including countries without restrictions such as the FDA risk evaluation and mitigation strategy requirement; Whereas medication abortion accounted for more than half of all abortions in the United States in 2021; Whereas following the decision of the Supreme Court of the United States in Dobbs v. Jackson Women's Health Organization, 142 S. Ct. 2228 (2022), to overturn decades of precedent in Roe v. Wade, 410 U.S. 113 (1973), and Planned Parenthood v. Casey, 505 U.S. 833 (1992), several States moved to further restrict access to abortion care, compounding an already complex landscape and exacerbating the existing abortion access crisis; Whereas, as of December 13, 2023, 17 States have filed bills with antimedication abortion provisions, and multiple States, including Florida, North Carolina, and Wyoming, have enacted restrictions on medication abortion; Whereas mere months after the decision of the Supreme Court of the United States to overturn Roe v. Wade, 410 U.S. 113 (1973), and Planned Parenthood v. Casey, 505 U.S. 833 (1992), in Dobbs v. Jackson Women's Health Organization, 142 S. Ct. 2228 (2022), antiabortion groups have filed baseless claims against the FDA over the approval of mifepristone, in an attempt to remove mifepristone from the market; Whereas the impact to the health and well-being of patients across the country would be devastating if mifepristone were taken off the market; Whereas abortion bans and restrictions force patients to travel greater distances for care and face longer wait times, and force some patients who are unable to access care to remain pregnant against their will